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Abstract 
We determined the expression of isoforms of prostaglandin H synthase (PGHS) and thromboxane A synthase (TXAS) in a human 
megakaryocyte cell line (MEG-01. The basal levels of full-length TXAS mRNA and the 60 kDa TXAS protein were high when compared 
to those of PGHS-1 and PGItS-2 in uninduced cells. Despite a high TXAS level, uninduced MEG-01 cells synthesized only a small 
amount of thromboxane A 2 (TXA 2) due to limited PGHS-1 or PGHS-2 expressions. Following PMA induction there was little change in 
TXAS. PGHS-2 mRNA was significantly increased at only 3 h of PMA treatment and the level declined rapidly, whereas PGHS-1 mRNA 
and protein levels were concordantly stimulated. Induction of PGHS-1 reached plateau on day 3 of PMA treatment. Analysis of 
arachidonate metabolism in cells induced by PMA for 3 and 5 days showed a high level of PGH 2 synthesis which exceeded the TXAS 
capacity for TXA 2 synthesis. Only traces of PGHS-2 mRNA and alternate-spliced TXAS mRNA were detected in human platelets. We 
conclude that TXAS and PGHS are differentially expressed in MEG-01 during PMA-induced ifferentiation. 
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1. Introduction 
Thromboxane A 2 (TXA 2) is a biologically active com- 
pound. It induces platelet secretion and aggregation and 
constricts arteries [1]. I1 plays an important role in 
hemostasis, thrombosis and several other diseases includ- 
ing adult respiratory distress syndrome and septic shock. 
Platelets and macrophages are the major source of TXA 2. 
Biosynthesis of TXA 2 in these cells requires a series of 
enzymes: (1) phospholipase A 2 (PLA2); (2) prostaglandin 
H synthase (PGHS); and (3) thromboxane A 2 synthase 
(TXAS). PLA 2 liberates arachidonic acid (AA) from the 
sn-2 position of membrane phospholipids. PGHS is a 
bifunctional enzyme. The: cyclooxygenase catalyzes the 
oxygenation of AA to form prostaglandin G 2 (PGG 2) and 
peroxidase activity catalyzes the reduction of PGG 2 to 
prostaglandin H 2 (PGH2). TXAS catalyzes the final con- 
version of PGH 2 to TXA:, [2]. 
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Two isoforms of PGHS have been identified and char- 
acterized [3-10]. The constitutive form, PGHS-1, is ex- 
pressed in most mammalian cells whereas the inducible 
form, PGHS-2, is expressed primarily in inflammatory 
cells [9,10]. The cDNA of TXAS has recently been cloned 
from lung and platelet sources. The full length cDNA from 
both sources is 1602 bp long, encoding a 534-amino acid 
protein [11]. An alternate-spliced TXAS mRNA was also 
detected in monocytic ell lines and lung tissues [12]. This 
alternate-spliced mRNA is 1380 bp long. A 163 bp seg- 
ment close to the 3'-end was spliced out. This shorter 
mRNA did not translate into detectable proteins in the 
cultured monocytic ell lines [12]. 
Human platelets appear to contain only the PGHS-1 
protein as detected on Western blot analysis using antibod- 
ies specific for PGHS-1. Expression of TXAS in platelets 
and megakaryocytes has not been investigated. Nor is the 
differentiation-induced xpressions of isoforms of PGHS 
and TXAS in megakaryocytes investigated. In this study 
we report the expression of these enzymes in human 
megakaryocytic cell line (MEG-01) with and without in- 
duction with phorbol 12-myristate 13-acetate (PMA). 
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2. Materials and methods 
2.1. Materials 
Phorbol 12-myristate 13-acetate (PMA), antibiotics, glu- 
tamine, RPMI 1640 medium, phosphate-buffered saline 
(PBS) and dimethyl sulfoxide (DMSO) were purchased 
from Sigma (St. Louis, MO). Fetal bovine serum was 
obtained from HyClone Laboratories (Logan, UT). Stock 
solutions of PMA were prepared in DMSO and stored at 
-20°C. All stock solutions were diluted appropriately 
with RPMI 1640 just before use. 
2.2. Preparation of human platelet microsomes 
Venous blood was collected from healthy human sub- 
jects into tubes containing 3.8% sodium citrate (v /v  = 9:1). 
Platelet rich plasma (PRP) was obtained by centrifuging 
the blood sample at 200 × g for 10 min. Platelets were 
pelleted by centrifugation of PRP at 1000 X g for 10 min, 
washed with PBS and sonicated in PBS containing 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 mM EDTA, 0.1% 
Triton X-100 and 0.03% leupeptin. After removing cell 
debris by additional centrifugation, platelet microsomes 
were isolated by centrifugation at 105000 ×g for 1 h. 
Platelet microsomal protein concentration was determined 
by bicinchoninic acid assay (BCA) using bovine serum 
albumin as standard [ 13]. 
2.3. Culture of MEG-O1 cells 
The human megakaryoblastic cell line was kindly pro- 
vided by Hidehiko Saito, Nagoya University, Japan. It was 
established from bone marrow samples obtained from a 
patient with Phi-positive chronic myelocytic leukemia in 
blastic crisis [14]. This cell line had been extensively 
characterized as belonging to the megakaryocytic l neage 
[15,16]. MEG-01 cells were cultured according to the 
procedure previously described [14]. They were cultured as 
suspension in RPMI 1640 medium supplemented with 
10% heat-inactivated fetal bovine serum, 2 mM glutamine, 
100 U/ml  penicillin and 50 /zg/ml streptomycin at 37°C 
in 5% CO 2 and 95% air in a humidified incubator. 
2.4. Induction of cell differentiation by PMA 
Ogura et al. [16] showed that PMA induced MEG-01 to 
undergo morphological and functional differentiation. In 
this study, we induced MEG-01 maturation according to 
their procedure. MEG-01 cells were incubated in cultured 
medium containing 10 -7 M PMA for 1-5 days. At each 
time point, cells were harvested and washed with PBS 
prior to experiments. We confirmed the observation by 
Ogura et al. [16] that 20-30% of cells were weakly 
adhered to the plastic surface after PMA induction. Adher- 
ent and non-adherent cells were separated and examined. 
There were no apparent differences in PGHS and TXAS 
enzyme masses or mRNA levels between adherent and 
nonadherent cells. These data were presented interchange- 
able and pooled. 
2.5. Assay of TXA 2 formation by radioimmunoassay 
Cells (3 • 105 cells/well) were washed twice with PBS 
and incubated with fresh PBS containing 10 /xM of AA at 
37°C for 10 min. The medium was collected and its TXB 2 
content was measured by a highly sensitive and specific 
RIA as previously described [17]. The protein concentra- 
tion of each cell preparation was determined and the data 
were reported as the amount of TXB 2 produced per /xg 
protein. 
2.6. Analysis of AA metabolites by HPLC 
To determine the ability of cultured cells in metaboliz- 
ing exogenously added AA, cells were washed twice with 
PBS and suspended in 1 ml of assay buffer (50 mM Tris 
HCI, pH 7.4). The washed cells (1 • 107 cells/mL) were 
incubated 10 min at 37°C with 10 ~M of [1-14C]AA (56 
mCi/mmol). After 10 min, the reaction was terminated by 
centrifugation at 13 000 rpm for 1 min at room tempera- 
ture, and the supernatant was removed and stored at - 20°C 
for HPLC analysis. Before HPLC analysis, eicosanoids in 
the conditioned medium were extracted using a Sep-Pak 
C18 cartridge (Waters, Milford, MA) [18]. The supematant 
was acidified with 4 ml of 25% methanol in 0.1% acetic 
acid water to remove polar substances. The AA metabo- 
lites were eluted with 5 mL of methanol. The methanol 
eluates were evaporated to dryness under nitrogen and the 
residue was redissolved in a small volume of methanol 
(100/~L). The entire sample was analyzed by reverse-phase 
HPLC according to a procedure previously described [19]. 
Internal standards had been used to determine the recovery 
of the eicosanoid generated. The identity of the radioactiv- 
ity peaks on the chromatograms was established by coelut- 
ing with authentic radiolabeled standards for the each of 
the eicosanoid metabolites. The order of elution was as 
follows: 6-keto-PGFt~ at 4.9 min; TXB 2 at 8.4 min; 
PGF2~ at 11.9 min; PGE 2 at 15.4 min; PGD 2 at 18.2 min; 
HHT (12-hydroxy-5,8,10-heptadecatrienoic acid) at 42 min; 
and AA at 60.2 min. 
2.7. Assay for PGHS and TXAS activities 
The PGHS activity was estimated by calculating the 
sum of all cyclooxygenase metabolites (TXB 2, PGE 2, 
PGF2~, HHT) detected on HPLC analysis after exogenous 
AA treatment at 37°C for 10 min. TXAS activity was 
assayed by incubating MEG-01 cells with PGH 2 (5 /xM) 
in 1 ml of 60 mM Tris-HC1 (pH 7.4) at 37°C for 5 min. 
The reaction was terminated by acidifying the mixture 
with 2 M HC1. The mixture was neutralized and the 
formation of TXB~ was measured by RIA. 
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2.8. Determination of PGHS and TXAS protein levels by 
Western blot 
The immunoblot was performed according to procedure 
previously described [20]. In brief, MEG-01 cells were 
lysed with PBS containing 0.1% Triton X-100, 1 mM 
PMSF, 0.01% EDTA and 0.03% leupeptin. The lysate was 
boiled for 3 min and centrifuged in an Eppendorf mi- 
crofuge at 13 000 rpm for 10 min. The protein concentra- 
tion in each sample was measured and 30 /xg of protein 
was applied to each lane on a 10% sodium dodecyl sulfate 
(SDS) polyacrylamide minigel and the proteins were sepa- 
rated by electrophoresis. The resolved proteins were trans- 
ferred electrophoretically at 200 mA for 1 h to a nitrocellu- 
lose membrane using a Bio-Rad Mini Trans-blot cell. The 
membrane was blocked with 1% milk in PBS and treated 
with antibodies pecific for the respective nzymes at 4°C 
overnight followed by goat anti-rabbit IgG conjugated with 
horseradish peroxidase and the peroxidase substrate 4- 
chloro-1-naphthol (Bio-Rad Laboratories, Richmond, CA). 
The intensity of the protein bands was estimated by a 
densitometer (Scan Jet Plus, Hewlett Packard, Greeley, 
CO). PGHS-1 protein was recognized by an affinity puri- 
fied rabbit polyclonal antibody directed against purified 
ovine PGHS-1. The optima.1 concentration f this antibody 
for Western blot was 8 /xg/ml. Standard for PGHS-1 was 
purified ovine PGHS-1 enzyme (Cayman Chemical Com- 
pany, Ann Arbor, MI). PGHS-2 protein was detected by a 
specific rabbit polyclonal antibody against a synthetic hu- 
man PGHS-2 C-terminal peptide (Cayman) in a 1:1000 
dilution. This antibody was shown to be specific for 
PGHS-2 and did not recognize purified PGHS-1 protein. 
Purified ovine PGHS-2 protein (M r 72000; Cayman) was 
included as a standard. TXAS protein was identified by an 
affinity-purified rabbit IgG directed against human TXAS 
as previously described [21]. The antibody concentration 
used in these experiments was 10 /xg/ml. Normal human 
platelet microsomal proteins were used as reference for 
TXAS. 
2.9. Detection of TXAS mRNA by RT-PCR 
Total RNA was extracted from MEG-01 cells and 
platelets by the method of Chomczynski and Sacchi [22]. 
Expression of TXAS transcripts in uninduced and PMA-in- 
duced MEG-01 cells was evaluated by reverse transcrip- 
tion-polymerase chain reaction (RT-PCR) procedure using 
Gene Amp RNA-PCR kit (Perkin Elmer, Norwalk, CT). It 
was performed on total cellular RNA (1 /zg) that was 
converted to cDNA by incubation for 60 min at 37°C with 
2.5 mM oligo d(T)16. Primers used for PCR were 5'-AT- 
TGCAGAGACGCTGAGGAT-3' and 5'-AGCATTTAG- 
GAAATGTTATGTAA-3', which are 1191-1210 bp and 
1738-1760 bp downstream from the translation start codon 
of TXAS-1 [12]. PCR was performed in a Perkin Elmer 
Cetus DNA thermal cycler for 35 cycles (each cycle is 
94°C 1 min, 52°C 1 min and 72°C 1 min). After amplifica- 
tion, the PCR products were resolved in a 2% agarose gel. 
The full-length TXAS mRNA was expected to produce a 
563 bp fragment, while the alternate spliced TXAS mRNA 
a 400 bp fragment [12]. 
2.10. Detection of PGHS-1 and PGHS-2 mRNA 
The relative mRNA levels for both isoforms were mea- 
sured by RT-PCR using Gene Amp EZ rTth RNA PCR kit 
(Perkin Elmer, Norwalk, CT) which employs a recombi- 
nant enzyme Thermus thermophilus DNA polymerase, as 
thermoactive r verse transcriptase and thermostable DNA 
polymerase. Primers for PGHS-1 amplification were 5'- 
GGAAGAAGCAGTTGCCAGATG-3 '  and 5'- 
TAAATGTGGCCGAGGTCTACC-3'. These primers cor- 
respond to the first 21 bp of exon 6 and 21 bp of exon 7 of 
the PGHS-1 gene, respectively [23]. Primers for PGHS-2 
mRNA were as described [8]. Homology between PGHS-1 
and PGHS-2 cDNA in this particular egion is very low. 
PCR products generated by PGHS-1 and PGHS-2 specific 
primers are 201 bp and 304 bp, respectively. PCR products 
were identified by digestion with restriction enzymes StuI 
and MseI. The 201 bp PGHS-1 PCR product contains a 
StuI restriction site which is expected to generate a 168 bp 
fragment and a 33 bp fragment following StuI digestion 
[23]. PGHS-2 PCR product does not have the StuI restric- 
tion site but the 304 bp product was cleaved by MseI into 
a 169 bp fragment and a 135 bp fragment. As a control, 
glycerolaldehyde 3'-phosphate dehydrogenase (G3PDH or 
GAPDH) was amplified from the same total RNA samples 
(1 /~g) used for PGHS and TXAS mRNA determination. 
Primers for the amplification of GAPDH mRNA were 
purchased from Clontech (Palo Alto, CA). The amplified 
PCR fragment was 983 bp long. 
3. Results 
3.1. mRNA levels detected by RT-PCR 
Low levels of PGHS-1 and -2 mRNA were detected by 
RT-PCR in uninduced MEG-01 cells (Fig. 1A). Previous 
studies have shown PMA induced MEG-01 cells to differ- 
entiate in a time-dependent manner [16] and platelet-like 
particles are generated after 5 days of PMA treatment. We 
therefore treated MEG-01 cells with PMA (10 -7 M) for 3, 
24, 48, 72, 96 and 120 h and extracted RNA from these 
cells at each time point for PGHS-1, PGHS-2 and TXAS 
mRNA determinations by RT-PCR. Only small changes in 
PGHS-1 mRNA levels were observed following PMA 
induction. Its level was slightly reduced at 3 h, slightly 
increased at 24 h and did not increase thereafter (Fig. 1A, 
lanes 3-7). The PGHS-2 mRNA level was markedly in- 
creased over the basal level at 3 h (Fig. 1A, lane 11) and 
the level remained steady (lanes 11-14) until 72 h, when it 
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declined (lanes 15 and 16). Platelet PGHS-I mRNA level 
(lane 8) was comparable to that of MEG-01 cells treated 
with PMA for 5 days. The PGHS-2 mRNA signal in 
platelets (lane 17) was only barely detectable and might be 
dubious. The GAPDH mRNA levels were unaltered by 
PMA induction. 
Fig. 1B shows that the level of the full-length TXAS 
mRNA (563 bp by RT-PCR) in uninduced MEG-01 cells 
was highly detectable and there was no apparent increase 
in its level following PMA induction. The alternate-spliced 
form (400 bp by RT-PCR) was also detectable in the 
uninduced cells and its level was only slightly altered by 
PMA induction. The changes were, however, not time 
dependent and may be due to RT-PCR variations. Platelets 
contained a highly detectable amount of full-length TXAS 
mRNA but a very low quantity of the alternate-spliced 
mRNA (lane 9 of Fig. lB.). 
3.2. PGHS and TXAS protein levels and enzyme activities 
Uninduced MEG-01 possessed only a trace amount of 
PGHS-1 and PGHS-2 proteins (Fig. 2A and 2B, lane 3). 
The PGHS-1 protein level in MEG-01 cells was steadily 
increasing after PMA treatment (Fig. 2A, lanes 5-8) and 
reached plateau on day 3 of PMA treatment. The molecu- 
lar size of PGHS-1 in MEG-01 cells was comparable to 
that in platelets (Fig. 3A, lanes 1 and 2). PGHS-2 protein 
was undetectable in platelets (data not shown). Its level 
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Fig. 1. Analysis of PGHS-1, PGHS-2 and TXAS mRNA in MEG-01 cells and platelets by RT-PCR. The DNA bands were visualized under UV after 
staining with ethidium bromide. (A) RT-PCR products of PGHS-1 (lanes 1-8) and PGHS-2 (lanes 10-17). Lane 1: control MEG-01 cells; lanes 2-7: 
MEG-01 induced with PMA for 3 h, 1, 2, 3, 4 and 5 days, respectively; lane 8: platelets, lane 9: molecular weight marker; lanes 10-17: same order of 
samples as in lanes 1-8. In the upper part of picture are 983 bp RT-PCR products of G3PDH prepared from the same RNA samples. (B) RT-PCR products 
of TXAS. Lane 1: molecular weight marker; lane 2: control MEG-01; lanes 3-8:MEG-01 induced with PMA for 3 h, 1, 2, 3, 4, and 5 days, respectively; 
lane 9: platelets. The 983 bp band is GAPDH, 563 band is full-length TXAS mRNA, 400 bp band is alternate spliced mRNA. 
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Fig. 2. Detection of PGHS-1, PGHS-2 and TXAS proteins in MEG-01 cells by Western blot. (A) Immunoblot with a PGHS-1 specific affinity-purified 
polyclonal antibody. Lane 1: the molecular weight marker; lane 2: purified PGHS-1 standard (30 ng); lane 3: uninduced MEG-01; lanes 4-8:MEG-01 
cells induced with PMA for 1, 2, 3, 4 and 5 days, respectively. (B) Immunoblot with a polyclonal antibody against a synthetic human PGHS-2 C-terminal 
peptide. Lane 1: molecular weight marker; lane 2: purified ovine PGHS-2 standard (12 /.~g); lane 3: uninduced MEG-0r cells; lane 4-9:MEG-01 induced 
with PMA for 3 h, 1, 2, 3, 4 and 5 days, respectively. (C) Immunoblot with TXAS specific polyclonai antibody. Lane 1: uninduced MEG-01; lanes 2-6: 
MEG-01 induced with PMA for 1-5 days; lane 7: TXAS reference (platelet microsomal proteins); lane 8: molecular weight marker. 
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was low in uninduced MEG-01 cells (Fig. 2B, lane 3) but 
increased significantly at only 3 h of PMA induction (lane 
4). The level, however, declined rapidly thereafter. Two 
additional bands which formed a triplet with the PGHS-2 
band were noticeable (Fig. 2B, lanes 5-9).  The elec- 
trophoretic mobility of the ovine PGHS-2 standard was 
slightly slower than that of human MEG-01 PGHS-2 pro- 
teins. 
The PGHS activity in MEG-01 cells was estimated 
from the HPLC analysis. The PGHS activity in uninduced 
cells was 1.5 ng/106 cells per 10 min, which was in- 
creased to 8.1 after 1 day, 15.8 after 3 days and 15.1 
ng/106cel ls per 10 min after 5 days of PMA treatment. A 
larger increase in PGE 2 and HHT than TXB 2 on day 3 and 
thereafter was attributed to an almost 10-fold increase in 
PGHS activity which generated a large quantity of PGH 2. 
Only a fraction of the PGH 2 generated was converted 
enzymatically by TXAS to TXA 2 and HHT, whereas the 
remaining fraction was converted primarily nonenzymati- 
cally to PGE 2 and HHT. 
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Fig. 3. Western blot analysis of PGHS-1 and TXAS proteins in normal human platelet micrososmal preparations. (A) Immunoblots with PGHS-1 antibody. 
Lanes 1 and 2: platelet microsomal preparations from two different healthy subjects; lane 3: purified PGHS-I standard; lane 4: molecular weight marker. 
(B) Immunoblot with TXAS antibody. Lane 1: molecular weight marker; lane 2: TXAS reference; lanes 3 and 4, platelet microsomal preparations from 
two different healthy subjects. 
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Fig. 4. Separation of eicosanoids produced by uninduced and PMA-induced MEG-01 cells by reverse-phase HPLC, Only relative radioactivity was shown. 
Days of PMA induction are shown at the right hand side of the chromatograph. 
The TXAS protein was constitutively present in an 
appreciable quantity in uninduced MEG-01 cells and its 
level was modestly increased by PMA induction (Fig. 2C). 
The TXAS band is 60 kDa, corresponding to platelet 
TXAS (Fig. 3B) and matched the molecular mass deduced 
from the full-length TXAS mRNA [12]. No lower molecu- 
lar mass form that may be, translated from the alternate- 
spliced mRNA was detectahle (Fig. 2C). TXAS activity in 
uninduced MEG-01, measured by its ability to convert 
PGH 2 to TXA 2, was e:~timated to be 129+24 pg 
TXB2//zg protein per 5 rnin. Following PMA induction, 
the enzyme activity increased by about 2-fold on day 1 
(223.9 _ 40 pg /~g per 5 min), 3-fold on day 3 (349.7 __. 31 
pg//xg per 5 min), and thereafter the activity remained 
steady up to day 5 ( 408.7 :+ 13 pg//xg per 5 min). 
Formation of arachidonate metabolites derived from 
exogenously added AA in uninduced MEG-01 cells and 
MEG-01 cells induced by PMA for different periods of 
time was evaluated using reverse-phase HPLC analysis. 
The results from a representative experiment are shown in 
Fig. 4. The uninduced cells produced only trace amounts 
of metabolites. TXB 2, HHT and PGE 2 peaks were signifi- 
cantly increased after 1 day of PMA treatment. Increase in 
the TXB 2 peak was lagging behind the HHT and PGE 2 
peaks after a longer period of PMA treatment. 
In addition, we measured biosynthesis of TXB 2 from 
exogenous AA by RIA. Uninduced cells produced 33 _ 7 
pg TXB 2/ /xg protein. Upon PMA induction, TXB 2 bio- 
synthesis increased about 3-fold on day 1 (111.1 -t- 10.5 
pg//.~g), further increased to approximately 6-fold on day 
3 (198 +__ 17 pg//~g), and after that did not changed signif- 
icantly (213.6 _ 19 pg//~g on day 5). These results howed 
that uninduced MEG-01 cells were capable of converting 
exogenously added AA into TXA 2 and that TXB 2 produc- 
tion was maximal after 3 days of PMA induction. 
4. Discussion 
Our findings revealed a differential expression of PGHS 
and TXAS in uninduced and PMA-induced MEG-01 cells. 
The PGHS-1 and PGHS-2 mRNA and protein levels and 
the resultant PGHS activity were very low, whereas the 
full length TXAS mRNA and the TXAS enzyme activity 
were relatively high in uninduced cells. The alternate- 
spliced TXAS mRNA was detectable in the uninduced 
cells. Induction with PMA led to a rapid rise in PGHS-2 
mRNA. In our experiments, we found that the level of 
PGHS-2 mRNA was consistently increased by more than 
several-fold over the basal level at 3 hours of PMA 
induction. The rise was persistent for 72 h and declined 
substantially thereafter. In platelets, a trace and probably 
insignificant amount of PGHS-2 mRNA was detectable. 
The PGHS-2 protein levels were also increased by 
PMA induction but the time-course of its increases follow- 
ing PMA induction did not follow that of PGHS-2 mRNA. 
The rise in PGHS-2 protein was rapid, i.e., after only 3 h 
of PMA treatment, but the rise in PGHS-2 protein was 
abated at 24 h. The PGHS-2 protein band remained unal- 
tered thereafter despite acontinuing rise of PGHS-2 mRNA 
levels. Two additional bands of slightly different molecular 
weight were recognized by PGHS-2 antibodies. The reason 
for the expression the multiple bands is unclear. The 
discordance between PGHS-2 mRNA and PGHS-2 protein 
levels after PMA induction may be due to a posttranscrip- 
tional mechanism which prevents an efficient ranslation of 
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the expressed mRNA. By contrast, the PGHS-1 mRNA 
and protein are induced by PMA at a slower but steady 
pace. The time-course of rises in mRNA and protein levels 
was concordant. By day 3 after PMA induction, the 
PGHS-1 protein levels was more prominent than PGHS-2 
protein levels on Western blot. However, a quantitative 
comparison is impossible due to different affinities of 
antibodies for these two enzymes. 
Both forms of TXAS mRNA are present in uninduced 
cells and their levels are little altered by PMA induction. 
As observed in monocytoid cells, the spliced form is not 
translated into protein on Western blots, probably due to 
rapid degradation. The role that the spliced mRNA plays in 
modulating TXAS level and TXA 2 synthesis remains un- 
clear. It may be involved in controlling TXAS translation. 
The spliced mRNA detected in platelets probably repre- 
sents the remnant of the spliced form expressed in 
megakaryocytes. 
This study provides new insight into the 
differentiation-related TXA 2 biosynthesis in megakary- 
ocytes. In the uninduced cell, despite the expression of an 
appreciable amount of TXAS, TXA 2 synthesis i  very low 
due to expression of only very low levels of PGHS-1 and 
PGHS-2 in the resting cell. After maximal PMA induction 
on day 3, the limiting step appears to shift to TXAS. PGH 2 
generated from AA appears to exceed the capacity of 
TXAS. A substantial quantity of PGH 2 is converted to 
PGE 2. Whether this is entirely due to a straight difference 
in the enzyme mass between PGHS-1 and TXAS or due to 
compartmentation of the metabolites remains to be investi- 
gated. The reverse-phase HPLC analysis revealed that the 
free arachidonic acid was higher in maximally-induced 
cells than in uninduced cells (Fig. 4). We observed this 
paradoxical phenomenon i  other cells as well. The reason 
for this paradox is unclear at the present time. It is 
interesting to note that on HPLC analysis the basal level of 
12-HETE, an end product of 12-1ipoxygenase (12-LO) in 
MEG-01 cells was very low, which was not increased by 
PMA induction, despite the fact that 12-LO is a major 
enzyme in platelets. This result is in accordance with that 
of a previous report [24] which showed undetectable 12- 
HETE in quiescent HEL (human erythroleukemia) cells 
and the 12-HETE was only minimally increased by PMA 
induction. However, our results differ from that reported 
by Shepperd et al. [25], which showed a large increase in 
lipoxygenase-derived products in DAMI cells upon PMA- 
induction. These differences are most likely due to a 
different origin of these three megakaryocyte-like c ll 
lines. MEG-01 cells were derived from the marrow cells of 
a patient with chronic myelocytic leukemia [14], a member 
of the myeloproloferative syndrome. A marked reduction 
in platelet 12-LO mRNA, protein and activity has been 
reported in patients with myeloproliferative disorders [26]. 
It is, therefore, possible that MEG-01 cells contained low 
12-LO levels. 
Since platelets contain only PGHS-1 and TXAS to carry 
out their TXA 2 synthetic activities, why should PGHS-2 
and spliced TXAS mRNA be expressed in the megakary- 
ocytes is not clear. There are several possible xplanations. 
First, the expression of PGHS-2 isoform and spliced TXAS 
mRNA in MEG-01 cells may reflect he malignant nature 
of the cell, as discussed above. It should be mentioned, 
however, that the MEG-01 cell are capable of undergoing 
orderly differentiation with expression of almost all 
megakaryocyte-platelet membrane and intracellular 
molecules. Secondly, expressions of PGHS-2 and spliced 
TXAS mRNA in megakaryocytes may be important in 
regulating the expressions of PGHS-1 and TXAS to ensure 
an orderly transition of these two enzymes from megakary- 
ocytes to platelets. Thirdly, PGHS-2 may play a role in 
regulating cell differentiation and proliferation. Early in- 
duction of PGHS-2 may be important in megakaryocyte 
cell growth. The MEG-01 cells will be a useful model for 
further investigations of these important issues. 
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